Compare AGCO Corporation (AGCO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGCO Corporation vs Moderna, Inc. — how do they compare? AGCO Corporation trades at $113.73 (market cap $8.24B), while Moderna, Inc. trades at $74.71 (market cap $31.65B). The key difference: Moderna, Inc. is far larger — about 3.8× AGCO Corporation's market cap, and AGCO Corporation pays a 1.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AGCO | MRNA | |
|---|---|---|
Market Cap | $8.24B | $31.65B |
Sector | Industrials | Health |
52-Week High | $140.49 | $81.80 |
52-Week Low | $100.14 | $22.36 |
Enterprise Value | $10.41B | $27.74B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
Moderna (MRNA) trades at $79.77, up 0.01% on the day, with a bullish technical signal from moving averages and positive momentum from recent pipeline news. The stock has seen significant gains, driven by FDA progress on its mRNA flu vaccine and expansion into oncology and rare diseases. However, fundamentals show persistent losses, with a net income margin of -144.92% in 2025 and declining revenue from pandemic peaks, though quarterly EPS has beaten expectations recently.
The outlook is mixed: strong technical momentum and pipeline diversification offer upside, but high valuation ratios and sustained unprofitability pose risks. Analyst consensus is cautious with a $48.83 price target, suggesting 39% downside, indicating Wall Street sees limited near-term fundamental support despite recent bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
